NanoDOX™
Infectious Diseases
ClinicalActive
Key Facts
About Nanopharmaceutics
Nanopharmaceutics is a clinical-stage biotech focused on enhancing drug delivery through nanoparticle formulations, primarily for BCS Class II and IV small molecules. The company has a pipeline of nine clinical-stage programs across oncology, CNS, metabolic, and infectious disease indications, supported by a leadership team with a long track record in product development and government contracting. While privately held, it operates as a subsidiary of the public entity TRON Group Inc. (OTC: TGRP) and leverages affiliate Alchem Laboratories for discovery capabilities, positioning itself to address significant unmet needs in targeted drug delivery.
View full company profileOther Infectious Diseases Drugs
| Drug | Company | Phase |
|---|---|---|
| Next-generation mRNA Vaccines | BioNTech | Phase 1 |
| Genetic Molecular Tests | Eurobio Scientific | Commercial |
| Potential Human POC Diagnostics | MatMaCorp | Research |
| LEAPS Technology | CEL-SCI | Pre-clinical |
| Platform Vaccine Applications | Chimeron Bio | Discovery |
| FMN riboswitch modulator | Acellera | Pre-clinical |
| NP-G2-044 | Novita Pharmaceuticals | Pre-Clinical |
| Ramoplanin™ | Nanopharmaceutics | Clinical |